Copper Histidinate PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
12561-67-0
Molecular formula
C12H16CuN6O4
Molecular weight
371.84 g/mol
Drug class
Copper replacement agentcopper–histidine complex for parenteral supplementation
Mechanism of action
Provides bioavailable copper for cellular copper-dependent enzyme systems. Copper is required for normal activity of cytochrome c oxidase, lysyl oxidase, dopamine beta-hydroxylase and other cuproenzymes; replacement addresses systemic copper deficiency due to impaired transport.
Indications / reported uses
Treatment of paediatric patients with Menkes disease, including presymptomatic and symptomatic infants, under the product-specific copper histidinate indication; early initiation is important and use is specialist-directed
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Copper Histidinate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Copper Histidinate Permitted Daily Exposure (PDE) report (the Copper Histidinate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Copper Histidinate Occupational Exposure Limit (OEL) report (the Copper Histidinate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.